Intravitreal Aflibercept Injection (IAI) for Presumed Ocular Histoplasmosis Syndrome
Status:
Completed
Trial end date:
2015-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the efficacy and safety of intravitreal injection of
aflibercept for the treatment of Choroidal Neovascularization (CNV) secondary to presumed
ocular histoplasmosis syndrome (POHS).